Drug intelligence / Profile preview

(1Z)-4-(4-fluorophenyl)-2-methylidenebutan-1-imine

Development stage
Unknown
Modality
Small Molecules
01

Overview

(1Z)-4-(4-fluorophenyl)-2-methylidenebutan-1-imine is a small molecule compound with the chemical formula C11H12FN and a molecular weight of 177.22 g/mol. It is listed in DrugBank as an experimental drug, but there are no approved indications, clinical trials, or detailed pharmacological data available. Its mechanism of action, biological targets, and therapeutic uses have not been characterized in public databases[1].

Other names
DB08176DB-08176DB 08176
02

Targets

MAOB (Monoamine oxidase B)

Beyond the preview

Go deeper on (1Z)-4-(4-fluorophenyl)-2-methylidenebutan-1-imine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on (1Z)-4-(4-fluorophenyl)-2-methylidenebutan-1-imine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call